PCM
STML

Prelude Capital Management’s Stemline Therapeutics, Inc. STML Stock Holding History

Prelude Capital Management’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-322
Closed -$3K – 2280
2019
Q4 		$3K Buy
322
+106
+49% +$1.05K ﹤0.01% 1823
2019
Q3 		$2K Buy
216
+155
+254% +$2.03K ﹤0.01% 1631
2019
Q2 		$1K Buy
+61
New +$882 ﹤0.01% 1601
2016
Q4 		– Sell
-100
Closed -$1K – 1897
2016
Q3 		$1K Buy
+100
New +$813 ﹤0.01% 1551

Other funds holding STML

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

Prelude Capital Management's STML Position: Q1 2020 in Review

Prelude Capital Management sold out of Stemline Therapeutics, Inc. (STML) in Q1 2020, closing a stake of 322 shares — an estimated $3K sold.

Prelude Capital Management first reported a position in STML in Q3 2016 and held it in 4 quarters. The position peaked at $3K in Q4 2019. 94 funds tracked by Wall St. Rank hold STML as of Q1 2020.

  • Prelude Capital Management reported no remaining Stemline Therapeutics, Inc. position as of Q1 2020 after selling out during the quarter.
  • Prelude Capital Management sold 322 Stemline Therapeutics, Inc. shares in Q1 2020, an estimated $3K.
  • Prelude Capital Management first reported a position in Stemline Therapeutics, Inc. in Q3 2016 and held it in 4 quarters.
  • Prelude Capital Management's Stemline Therapeutics, Inc. position peaked at $3K in Q4 2019.
  • 94 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q1 2020.

Based on Prelude Capital Management's 13F filing for Q1 2020, filed 15 May 2020.